23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

Lilly strikes another billion-dollar deal – 15 acquisitions this year alone

Eli Lilly is continuing its expansion strategy with the acquisition of blood cancer biotech Calytrix Bio in a deal worth up to USD 1.5 billion.
Advertisement

Calytrix is developing treatments for myelofibrosis and essential thrombocythaemia, two rare blood disorders belonging to a group of conditions known as myeloproliferative neoplasms. The diseases are characterised by the overproduction of blood cells in the bone marrow and can lead to complications including bone marrow scarring and blood clots.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.094|